TY - JOUR
T1 - No major role for the EMX2 gene in schizencephaly
AU - Merello, Elisa
AU - Swanson, Eric
AU - De Marco, Patrizia
AU - Akhter, Murtaza
AU - Striano, Pasquale
AU - Rossi, Andrea
AU - Cama, Armando
AU - Leventer, Richard J.
AU - Guerrini, Renzo
AU - Capra, Valeria
AU - Dobyns, William B.
PY - 2008/5/1
Y1 - 2008/5/1
N2 - Schizencephaly (SCH) is a rare disorder of cerebral cortical development, characterized by full thickness clefts spanning the wall of the cerebral hemispheres that are lined and surrounded by polymicrogyric cortex. Based on pathological analysis, SCH was originally considered to have multiple causes including infectious and vascular injuries, and toxic agents. However, a few reports of familial SCH have suggested a possible genetic etiology. Ten years ago two articles identified EMX2 as the first causative gene for human SCH in 13 of 18 patients, although for several putative mutations no pathogenic role was demonstrated. Here, we reinterpret the original articles as showing a significantly lower mutational rate (17%) than originally reported (72%), and provide results of EMX2 sequencing in 39 new SCH patients, detecting no pathogenic mutations. We conclude that the reported association between SCH and EMX2 mutations is not adequately supported by current data, and that diagnostic testing of EMX2 is not justified, as any results would be uninterpretable.
AB - Schizencephaly (SCH) is a rare disorder of cerebral cortical development, characterized by full thickness clefts spanning the wall of the cerebral hemispheres that are lined and surrounded by polymicrogyric cortex. Based on pathological analysis, SCH was originally considered to have multiple causes including infectious and vascular injuries, and toxic agents. However, a few reports of familial SCH have suggested a possible genetic etiology. Ten years ago two articles identified EMX2 as the first causative gene for human SCH in 13 of 18 patients, although for several putative mutations no pathogenic role was demonstrated. Here, we reinterpret the original articles as showing a significantly lower mutational rate (17%) than originally reported (72%), and provide results of EMX2 sequencing in 39 new SCH patients, detecting no pathogenic mutations. We conclude that the reported association between SCH and EMX2 mutations is not adequately supported by current data, and that diagnostic testing of EMX2 is not justified, as any results would be uninterpretable.
UR - http://www.scopus.com/inward/record.url?scp=43049108399&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43049108399&partnerID=8YFLogxK
U2 - 10.1002/ajmg.a.32264
DO - 10.1002/ajmg.a.32264
M3 - Article
C2 - 18409201
AN - SCOPUS:43049108399
SN - 1552-4825
VL - 146
SP - 1142
EP - 1150
JO - American Journal of Medical Genetics, Part A
JF - American Journal of Medical Genetics, Part A
IS - 9
ER -